Last reviewed · How we verify
Ramipril or losartan
At a glance
| Generic name | Ramipril or losartan |
|---|---|
| Also known as | renin-angiotensin system (RAS) inhibitors |
| Sponsor | University Magna Graecia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction (PHASE4)
- Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. (PHASE4)
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography (NA)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril or losartan CI brief — competitive landscape report
- Ramipril or losartan updates RSS · CI watch RSS
- University Magna Graecia portfolio CI